Artelo Biosciences, Inc.
ARTL
$9.35
-$0.18-1.89%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 4.48M | 4.03M | 4.12M | 3.90M | 4.05M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 10.54M | 9.90M | 10.11M | 9.54M | 10.96M |
| Operating Income | -10.54M | -9.90M | -10.11M | -9.54M | -10.96M |
| Income Before Tax | -10.50M | -9.72M | -9.83M | -9.12M | -10.44M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -10.50 | -9.72 | -9.83 | -9.12 | -10.44 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -10.50M | -9.72M | -9.83M | -9.12M | -10.44M |
| EBIT | -10.54M | -9.90M | -10.11M | -9.54M | -10.96M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -21.26 | -20.17 | -20.54 | -19.18 | -22.54 |
| Normalized Basic EPS | -13.42 | -12.83 | -13.21 | -12.54 | -14.80 |
| EPS Diluted | -21.26 | -20.17 | -20.54 | -19.18 | -22.54 |
| Normalized Diluted EPS | -13.42 | -12.83 | -13.21 | -12.54 | -14.80 |
| Average Basic Shares Outstanding | 11.96M | 11.93M | 11.83M | 11.74M | 11.42M |
| Average Diluted Shares Outstanding | 11.96M | 11.93M | 11.83M | 11.74M | 11.42M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |